Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis

S. Gadau, C. Emanueli, S. Van Linthout, G. Graiani, M. Todaro, M. Meloni, I. Campesi, G. Invernici, F. Spillmann, K. Ward, P. Madeddu

Research output: Contribution to journalArticle

64 Citations (Scopus)

Abstract

Aims/hypothesis: Benfotiamine, a vitamin B1 analogue, reportedly prevents diabetic microangiopathy. The aim of this study was to evaluate whether benfotiamine is of benefit in reparative neovascularisation using a type I diabetes model of hindlimb ischaemia. We also investigated the involvement of protein kinase B (PKB)/Akt in the therapeutic effects of benfotiamine. Methods: Streptozotocin-induced diabetic mice, given oral benfotiamine or vehicle, were subjected to unilateral limb ischaemia. Reparative neovascularisation was analysed by histology. The expression of Nos3 and Casp3 was evaluated by real-time PCR, and the activation state of PKB/Akt was assessed by western blot analysis and immunohistochemistry. The functional importance of PKB/Akt in benfotiamine-induced effects was investigated using a dominant-negative construct. Results: Diabetic muscles showed reduced transketolase activity, which was corrected by benfotiamine. Importantly, benfotiamine prevented ischaemia-induced toe necrosis, improved hindlimb perfusion and oxygenation, and restored endothelium-dependent vasodilation. Histological studies revealed the improvement of reparative neovascularisation and the inhibition of endothelial and skeletal muscle cell apoptosis. In addition, benfotiamine prevented the vascular accumulation of advanced glycation end products and the induction of pro-apoptotic caspase-3, while restoring proper expression of Nos3 and Akt in ischaemic muscles. The benefits of benfotiamine were nullified by dominant-negative PKB/Akt. In vitro, benfotiamine stimulated the proliferation of human EPCs, while inhibiting apoptosis induced by high glucose. In diabetic mice, the number of circulating EPCs was reduced, with the deficit being corrected by benfotiamine. Conclusions/interpretation: We have demonstrated, for the first time, that benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. In addition, benfotiamine combats the diabetes-induced deficit in endothelial progenitor cells.

Original languageEnglish
Pages (from-to)405-420
Number of pages16
JournalDiabetologia
Volume49
Issue number2
DOIs
Publication statusPublished - Feb 2006

Fingerprint

Proto-Oncogene Proteins c-akt
Extremities
Apoptosis
Ischemia
Hindlimb
benphothiamine
Transketolase
Diabetic Angiopathies
Muscles
Advanced Glycosylation End Products
Thiamine
Toes
Therapeutic Uses
Streptozocin
Type 1 Diabetes Mellitus
Vasodilation
Caspase 3
Muscle Cells
Endothelium
Blood Vessels

Keywords

  • Advanced glycation end-products
  • AGEs
  • Angiogenesis
  • Apoptosis
  • Benfotiamine
  • Caspase
  • Diabetes
  • Endothelial progenitor cells
  • Ischaemia
  • Vitamin B1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. / Gadau, S.; Emanueli, C.; Van Linthout, S.; Graiani, G.; Todaro, M.; Meloni, M.; Campesi, I.; Invernici, G.; Spillmann, F.; Ward, K.; Madeddu, P.

In: Diabetologia, Vol. 49, No. 2, 02.2006, p. 405-420.

Research output: Contribution to journalArticle

Gadau, S, Emanueli, C, Van Linthout, S, Graiani, G, Todaro, M, Meloni, M, Campesi, I, Invernici, G, Spillmann, F, Ward, K & Madeddu, P 2006, 'Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis', Diabetologia, vol. 49, no. 2, pp. 405-420. https://doi.org/10.1007/s00125-005-0103-5
Gadau, S. ; Emanueli, C. ; Van Linthout, S. ; Graiani, G. ; Todaro, M. ; Meloni, M. ; Campesi, I. ; Invernici, G. ; Spillmann, F. ; Ward, K. ; Madeddu, P. / Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. In: Diabetologia. 2006 ; Vol. 49, No. 2. pp. 405-420.
@article{eb62683b6cbd415a93a975e627670c46,
title = "Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis",
abstract = "Aims/hypothesis: Benfotiamine, a vitamin B1 analogue, reportedly prevents diabetic microangiopathy. The aim of this study was to evaluate whether benfotiamine is of benefit in reparative neovascularisation using a type I diabetes model of hindlimb ischaemia. We also investigated the involvement of protein kinase B (PKB)/Akt in the therapeutic effects of benfotiamine. Methods: Streptozotocin-induced diabetic mice, given oral benfotiamine or vehicle, were subjected to unilateral limb ischaemia. Reparative neovascularisation was analysed by histology. The expression of Nos3 and Casp3 was evaluated by real-time PCR, and the activation state of PKB/Akt was assessed by western blot analysis and immunohistochemistry. The functional importance of PKB/Akt in benfotiamine-induced effects was investigated using a dominant-negative construct. Results: Diabetic muscles showed reduced transketolase activity, which was corrected by benfotiamine. Importantly, benfotiamine prevented ischaemia-induced toe necrosis, improved hindlimb perfusion and oxygenation, and restored endothelium-dependent vasodilation. Histological studies revealed the improvement of reparative neovascularisation and the inhibition of endothelial and skeletal muscle cell apoptosis. In addition, benfotiamine prevented the vascular accumulation of advanced glycation end products and the induction of pro-apoptotic caspase-3, while restoring proper expression of Nos3 and Akt in ischaemic muscles. The benefits of benfotiamine were nullified by dominant-negative PKB/Akt. In vitro, benfotiamine stimulated the proliferation of human EPCs, while inhibiting apoptosis induced by high glucose. In diabetic mice, the number of circulating EPCs was reduced, with the deficit being corrected by benfotiamine. Conclusions/interpretation: We have demonstrated, for the first time, that benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. In addition, benfotiamine combats the diabetes-induced deficit in endothelial progenitor cells.",
keywords = "Advanced glycation end-products, AGEs, Angiogenesis, Apoptosis, Benfotiamine, Caspase, Diabetes, Endothelial progenitor cells, Ischaemia, Vitamin B1",
author = "S. Gadau and C. Emanueli and {Van Linthout}, S. and G. Graiani and M. Todaro and M. Meloni and I. Campesi and G. Invernici and F. Spillmann and K. Ward and P. Madeddu",
year = "2006",
month = "2",
doi = "10.1007/s00125-005-0103-5",
language = "English",
volume = "49",
pages = "405--420",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Benfotiamine accelerates the healing of ischaemic diabetic limbs in mice through protein kinase B/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis

AU - Gadau, S.

AU - Emanueli, C.

AU - Van Linthout, S.

AU - Graiani, G.

AU - Todaro, M.

AU - Meloni, M.

AU - Campesi, I.

AU - Invernici, G.

AU - Spillmann, F.

AU - Ward, K.

AU - Madeddu, P.

PY - 2006/2

Y1 - 2006/2

N2 - Aims/hypothesis: Benfotiamine, a vitamin B1 analogue, reportedly prevents diabetic microangiopathy. The aim of this study was to evaluate whether benfotiamine is of benefit in reparative neovascularisation using a type I diabetes model of hindlimb ischaemia. We also investigated the involvement of protein kinase B (PKB)/Akt in the therapeutic effects of benfotiamine. Methods: Streptozotocin-induced diabetic mice, given oral benfotiamine or vehicle, were subjected to unilateral limb ischaemia. Reparative neovascularisation was analysed by histology. The expression of Nos3 and Casp3 was evaluated by real-time PCR, and the activation state of PKB/Akt was assessed by western blot analysis and immunohistochemistry. The functional importance of PKB/Akt in benfotiamine-induced effects was investigated using a dominant-negative construct. Results: Diabetic muscles showed reduced transketolase activity, which was corrected by benfotiamine. Importantly, benfotiamine prevented ischaemia-induced toe necrosis, improved hindlimb perfusion and oxygenation, and restored endothelium-dependent vasodilation. Histological studies revealed the improvement of reparative neovascularisation and the inhibition of endothelial and skeletal muscle cell apoptosis. In addition, benfotiamine prevented the vascular accumulation of advanced glycation end products and the induction of pro-apoptotic caspase-3, while restoring proper expression of Nos3 and Akt in ischaemic muscles. The benefits of benfotiamine were nullified by dominant-negative PKB/Akt. In vitro, benfotiamine stimulated the proliferation of human EPCs, while inhibiting apoptosis induced by high glucose. In diabetic mice, the number of circulating EPCs was reduced, with the deficit being corrected by benfotiamine. Conclusions/interpretation: We have demonstrated, for the first time, that benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. In addition, benfotiamine combats the diabetes-induced deficit in endothelial progenitor cells.

AB - Aims/hypothesis: Benfotiamine, a vitamin B1 analogue, reportedly prevents diabetic microangiopathy. The aim of this study was to evaluate whether benfotiamine is of benefit in reparative neovascularisation using a type I diabetes model of hindlimb ischaemia. We also investigated the involvement of protein kinase B (PKB)/Akt in the therapeutic effects of benfotiamine. Methods: Streptozotocin-induced diabetic mice, given oral benfotiamine or vehicle, were subjected to unilateral limb ischaemia. Reparative neovascularisation was analysed by histology. The expression of Nos3 and Casp3 was evaluated by real-time PCR, and the activation state of PKB/Akt was assessed by western blot analysis and immunohistochemistry. The functional importance of PKB/Akt in benfotiamine-induced effects was investigated using a dominant-negative construct. Results: Diabetic muscles showed reduced transketolase activity, which was corrected by benfotiamine. Importantly, benfotiamine prevented ischaemia-induced toe necrosis, improved hindlimb perfusion and oxygenation, and restored endothelium-dependent vasodilation. Histological studies revealed the improvement of reparative neovascularisation and the inhibition of endothelial and skeletal muscle cell apoptosis. In addition, benfotiamine prevented the vascular accumulation of advanced glycation end products and the induction of pro-apoptotic caspase-3, while restoring proper expression of Nos3 and Akt in ischaemic muscles. The benefits of benfotiamine were nullified by dominant-negative PKB/Akt. In vitro, benfotiamine stimulated the proliferation of human EPCs, while inhibiting apoptosis induced by high glucose. In diabetic mice, the number of circulating EPCs was reduced, with the deficit being corrected by benfotiamine. Conclusions/interpretation: We have demonstrated, for the first time, that benfotiamine aids the post-ischaemic healing of diabetic animals via PKB/Akt-mediated potentiation of angiogenesis and inhibition of apoptosis. In addition, benfotiamine combats the diabetes-induced deficit in endothelial progenitor cells.

KW - Advanced glycation end-products

KW - AGEs

KW - Angiogenesis

KW - Apoptosis

KW - Benfotiamine

KW - Caspase

KW - Diabetes

KW - Endothelial progenitor cells

KW - Ischaemia

KW - Vitamin B1

UR - http://www.scopus.com/inward/record.url?scp=31844452060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31844452060&partnerID=8YFLogxK

U2 - 10.1007/s00125-005-0103-5

DO - 10.1007/s00125-005-0103-5

M3 - Article

C2 - 16416271

AN - SCOPUS:31844452060

VL - 49

SP - 405

EP - 420

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 2

ER -